Efficient Multiproduct Process Development Case Study - Achieving multiproduct development within shortened timelines. - BioPharm International

ADVERTISEMENT

Efficient Multiproduct Process Development Case Study
Achieving multiproduct development within shortened timelines.


BioPharm International
Volume 24, Issue 7, pp. 35-43

GAINING EFFICIENCY THROUGH PD BUSINESS PROCESSES

To better coordinate the generation and execution of an integrated development plan, a structured PD team (PDT) process was established. Each team consists of a representative from each of the four disciplines (i.e., cell culture, purification, analytical, and pharmaceutical development) and from manufacturing technical support. Each team has a leader and a project manager; these individuals are responsible for driving the planning, coordinating activities, and tracking execution against the goals. The team leader is responsible for driving decisions, mitigating problems, and representing the process develpment department at higher level teams, such as CMC teams. One PDT is designated to champion each development program. The teams are sponsored by PD management, who provide strategic input into the project plans, and align and prioritize resources across projects.


Figure 5: Process development (PD) team business process diagram. A structured business process allows for consistent planning, prioritizing, and delivery on multiple programs in a resource-constrained and time-limited business. The inputs into process development work (top box) come from a wide range of stakeholders (right tall box) and vary in scope from product development strategy to a specific request such as responding to a regulatory question. The inputs are organized into an integrated process development plan with key goals and milestones (beginning of cycle). The PD teams drive compilation of such goals and milestones and integrating them into a detailed plan through iterative coordination with line functions. Work is prioritized and resources allocated by management and executed by functions. The team updates are one of the outputs of the team, which are periodically reviewed for strategic guidance or realignment as needed. Data, recommendations, and materials are other team outputs that are provided to the stakeholders to complete the circle of product-development interdependencies.
Figure 5 depicts the PDT process for planning, prioritization, execution, and communication. Based on the inputs from external and internal stakeholders, the PDTs develop an integrated PD life cycle plan for each project, including detailed milestones and success criteria for each stage. The plans, the status, and the decision points for all teams are reviewed and prioritized by PD department management as the plans are being executed by the line functions. Periodic review of status and risks facilitate timely cross-functional decision making, raise awareness of current program problems, and provide cross-functional learning. The deliverables are also communicated or provided to external stakeholders in the appropriate forums, who might then give additional input.

The effectiveness of PD is enhanced by establishing team structures, optimizing business processes, developing clear expectations for roles and responsibilities, and committing the organization to build, train, and mentor strong teams as centers of excellence in product development.

CONCLUSION

PD can be the leverage in product development performance where the speed and effectiveness of learning from each program to develop and implement process technologies can shape the overall cost, timelines, and results of new product introductions. PD life cycle planning enables a disciplined approach to PD for a given product and facilitates learning across programs to minimize rework. Establishing an integrated approach among the four disciplines of PD to answer critical questions early in the development cycle ensures timely and appropriate adjustments to the overall program plan and better use of resources. The development and application of process platforms with small-scale models that are predictive of manufacturing-scale performance leads to cost effective product development. Establishing a business process that facilitates integrated planning and decision making is a precursor to well-coordinated execution. Overall, PD life cycle planning, combined with continuous business process improvements, allows for efficient delivery within the fast-to-market complex biological product development paradigm.

ACKNOWLEDGMENTS

The evolution of process platforms has been a result of the efforts led by Yas Saotome, previous head of cell culture process development at Shire (currently at Alexion Pharmaceuticals) and David Nichols, head of purification process development. The analytical automation technologies were introduced by the immunoassay and bioassay group (Jeffrey vanDoren and Laura Trubiano, led by Brian Lentrichia). The authors acknowledge the inputs into the PD life cycle by Chun Zhang (current head of cell culture process development), David Nichols, PD project managers (Jennifer Puhlhorn and Jennifer Terew) and Walter Uchendu. The insights of Matt Croughan, Rathmann Professor at Kegg Graduate Institute, on the process development learning modes are highly appreciated.

CURRENT AFFILIATIONS

Zahra Shahrokh is currently senior vice-president at Aurabiosciences, and Marcio Voloch is currently a biotechnology consultant.

Zahra Shahrokh* was senior director, pharmaceutical and analytical development, Stacy Price* is director, process development operations, and Marcio Voloch was vice-president, process development, all at Shire Human Genetic Therapies, Cambridge MA. *To whom correspondence should be addressed,
or
.

REFERENCES

1. G.P. Pisano, The Development Factory: Unl.ocking the Potential of Process Development. (Harvard Business Press, Boston, MA, 1997).

2. J. Muenzer et al., Genet. Med. 8 (8), 465–473 2006.

3. Y.H. Xu, et al., PLoS ONE 5 (5) e10750, 2010.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Author Guidelines
Source: BioPharm International,
Click here